

(51) International Patent Classification:
G01N 33/50 (2006.01)(21) International Application Number:
PCT/IL2015/050663(22) International Filing Date:
25 June 2015 (25.06.2015)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
62/016,773 25 June 2014 (25.06.2014) US(71) Applicant: TEL HASHOMER MEDICAL RESEARCH
INFRASTRUCTURE AND SERVICES LTD. [IL/IL];
The Chaim Sheba Medical Center, Tel HaShomer,
5262000 Ramat-Gan (IL).(72) Inventors: DEKEL, Benjamin; 40 Sokolov Street,
6248509 Tel-Aviv (IL). HARARI-STEINBERG, Orit; 87
HaHagana Street, 43312 RaAnana (IL).(74) Agents: EHRLICH, Gal et al.; G. E. Ehrlich (1995) Ltd.,
11 Menachem Begin Road, 5268104 Ramat Gan (IL).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: IDENTIFICATION OF CANCER STEM CELLS AND USE OF SAME FOR DIAGNOSIS AND TREATMENT

FIG. 1A

(57) Abstract: A method of identifying cancer stem cell
markers in a human primary tumor is disclosed. The method
comprises: (a) in vivo passaging the primary tumor; and (b)
comparing a level of at least one antigen in a first population
of passaged tumor cells of the primary tumor with a second
population of tumor cells of the primary tumor, wherein an
increase in the amount of the antigen in the first population
of tumor cells as compared to the amount of the antigen in
the second population of tumor cells is indicative of a cancer
stem cell marker in the human primary tumor.



Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*